Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997018241) INDUCING RESISTANCE TO TUMOR GROWTH WITH SOLUBLE IGF-1 RECEPTOR
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/018241 International Application No.: PCT/US1996/018327
Publication Date: 22.05.1997 International Filing Date: 13.11.1996
Chapter 2 Demand Filed: 12.06.1997
IPC:
A61K 38/00 (2006.01) ,C07K 14/72 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
72
for hormones
Applicants:
THOMAS JEFFERSON UNIVERSITY [US/US]; 11th and Walnut Streets Philadelphia, PA 19107, US
Inventors:
BASERGA, Renato; US
RESNICOFF, Mariana; US
D'AMBROSIO, Consuelo; US
FERBER, Andre; US
Agent:
JOHNSON, Philip, S. ; Woodcock Washburn Kurtz Mackiewicz & Norris 46th floor One Liberty Place Philadelphia, PA 19103, US
Priority Data:
60/006,69914.11.1995US
Title (EN) INDUCING RESISTANCE TO TUMOR GROWTH WITH SOLUBLE IGF-1 RECEPTOR
(FR) METHODE POUR PROVOQUER UNE RESISTANCE A LA CROISSANCE DE TUMEURS AU MOYEN D'UN RECEPTEUR DE IGF-1 SOLUBLE
Abstract:
(EN) Individuals having tumors are treated with pharmaceutical compositions comprising expression vectors, preferably adenovirus or retroviruses, comprising nucleic acid molecules encoding soluble IGF-1R. Such vectors express soluble IGF-1R in tumor cells resulting in reversal of the transformed phenotype, induction of apoptosis, and inhibition of tumorigenesis.
(FR) Selon l'invention, les sujets présentant des tumeurs sont traités avec des compositions pharmaceutiques contenant des vecteurs d'expression, de préférence des adénovirus ou des rétrovirus, comportant des molécules d'acide nucléique codant le IGF-1R soluble. Ces vecteurs expriment, dans les cellules tumorales, le IGF-1R soluble qui entraîne une inversion du phénotype transformé, provoque l'apoptose et inhibe l'oncogenèse.
Designated States: CA, JP
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0861267JP2000500654 CA2235695